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Abstract 
Rationale: Pupillometry can be used to characterize autonomic drug effects. Objective: To 
determine the autonomic effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) 
on pupillary function, administered alone and after pretreatment with reboxetine, duloxetine, 
clonidine, carvedilol, and doxazosin. Methods: Infrared pupillometry was performed in five 
placebo-controlled randomized clinical studies. Each study included 16 healthy subjects 
(eight men, eight women) who received placebo-MDMA (125 mg), placebo-placebo, 
pretreatment-placebo, or pretreatment-MDMA using a crossover design. Results: MDMA 
produced mydriasis, reduced the response to light, prolonged the latency to the light reflex, 
and shortened the recovery time. The impaired reflex response was short-lasting and 
associated with subjective, cardiostimulant, and hyperthermic drug effects and returned to 
normal within 5-6 h after MDMA administration when plasma MDMA levels were still high. 
Mydriasis was associated with the changes in plasma MDMA concentration over time and 
longer-lasting. Both reboxetine and duloxetine interacted with the effects of MDMA on 
pupillary function. Duloxetine even prevented MDMA-induced impairments in the light reflex 
response despite having similar effects when administered alone. Clonidine did not 
significantly reduce the mydriatic effects of MDMA, although it produced miosis when 
administered alone. Carvedilol and doxazosin did not alter the effects of MDMA on pupillary 
function. Conclusions: The MDMA-induced prolongation of the latency  in the pupillary light 
reflex response and the reduction of light-induced miosis indicate indirect central 
parasympathetic inhibition, and the faster recovery time reflects an increased direct 
sympathomimetic action. Both norepinephrine and serotonin mediate the effects of MDMA 
on pupillary function. While MDMA-induced mydriasis is lasting and mirrors the plasma 
concentration-time curve of MDMA, the impairment in the reaction to light is associated with 
the subjective and other autonomic effects induced by MDMA and exhibits acute tolerance. 
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Introduction 
 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) induces the transporter-
mediated release of serotonin and norepinephrine (Liechti and Vollenweider 2001; Rothman 
et al. 2001; Verrico et al. 2007) and produces cardio- and psychostimulant effects in humans 
(Hysek et al. 2011). The autonomic sympathomimetic effects of MDMA in humans include 
increases in blood pressure, heart rate, body temperature, and pupil diameter (Farre et al. 
2004, 2007; Hysek et al. 2012c; Kolbrich et al. 2008; Liechti et al. 2001; Mas et al. 1999). 
Pupil size and the response to a flashlight stimulus are typically assessed in the evaluation 
of intoxicated patients. Mydriasis is a clinical hallmark of sympathomimetic toxicity in cases 
of ecstasy or cocaine use. Laboratory studies have also shown an increase in pupil diameter 
after MDMA administration (Farre et al. 2004, 2007; Kolbrich et al. 2008; Mas et al. 1999). 
However, unknown are whether MDMA alters the pupillary light reflex response and how 
pupillary changes are linked to MDMA exposure and the subjective effects of the drug. 
Additionally, the pharmacological mechanism by which MDMA produces mydriasis and 
potential changes in pupillary function are unclear. Mydriasis and alterations in the pupillary 
light reflex may result from increased sympathetic activity, the release of norepinephrine, and 
1-adrenergic receptor stimulation directly in the iris or from a decrease in parasympathetic 
activity (Loewenfeld 1999). At the level of the iris, the latency to the light reflex and miotic 
response to light are thought to reflect parasympathetic activation (Heller et al. 1990; 
Loewenfeld 1999), whereas redilation is considered to mainly reflect sympathetic activation 
(Loewenfeld 1999; Morley et al. 1991). Notably, the parasympathetic input to the pupil may 
also be inhibited centrally via 2-adrenergic receptors in the Edinger-Westphal nucleus by an 
increase in sympathetic activity (Phillips et al. 2000a; Siepmann et al. 2007; Szabadi and 
Bradshaw 1996). Furthermore, the serotonin system has been shown to indirectly influence 
pupillary function, possibly by enhancing sympathetic activity (Prow et al. 1996). Therefore, 
the MDMA-induced release of norepinephrine in the periphery may stimulate 1-adrenergic 
receptors in the iris or inhibit parasympathetic activity via central 2-adrenergic receptors in 
the Edinger-Westphal nucleus. The adrenergic mechanisms may be further enhanced by the 
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potent MDMA-induced release of serotonin. To explore the mechanism of action of MDMA 
on pupillary function, we investigated the effects of five pretreatments on the response to 
MDMA. We used the norepinephrine transporter inhibitor reboxetine to block the transporter-
mediated, MDMA-induced release of norepinephrine (Hysek et al. 2011; i.e., the indirect 
sympathomimetic effect of MDMA). The serotonin and norepinephrine transporter inhibitor 
duloxetine was similarly used to block the MDMA-induced, transporter-mediated release of 
both serotonin and norepinephrine (Simmler et al. 2011). The 2-adrenergic agonist clonidine 
was used as a sympathicolytic to inhibit the transporter-independent vesicular release of 
norepinephrine (Hysek et al. 2012a). Carvedilol and doxazosin were used to block 
postsynaptic 11-3- and 1-adrenergic receptors, respectively (Hysek et al. 2012c; i.e., to 
directly antagonize the effects of norepinephrine in the iris, on the cardiovascular system, 
and on body temperature). The large series of studies included additional outcome 
measures presented elsewhere (Hysek et al. 2011, 2012a, b, d; Simmler et al. 2011).  
 
Material and Methods 
Study design 
 This was a pooled analysis of five double-blind, double-dummy placebo-controlled, 
randomized, crossover studies (Hysek et al. 2011, 2012a, b, d; Simmler et al. 2011). The 
primary aim of the pooled analysis was to assess the effects of MDMA on pupil size and the 
pupillary light reflex compared with placebo in all 80 subjects and explore associations with 
the pharmacokinetics of MDMA and other pharmacodynamic measures. All of the subjects 
included in the five studies received MDMA, placebo, one of five different pretreatments prior 
to MDMA, or the pretreatment alone (Fig. 1). Thus, the four experiential conditions for all of 
the subjects were placebo-placebo, pretreatment-placebo, placebo-MDMA, and 
pretreatment-MDMA in a balanced order. Each of the five studies included 16 subjects (eight 
male, eight female). The pretreatments used in the five studies were reboxetine, duloxetine, 
clonidine, carvedilol, and doxazosin. The random allocation sequence was developed by a 
clinical pharmacist and concealed from all of the individuals involved in study management. 
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The washout periods between sessions were ≥ 10 days. The studies were conducted in 
accordance with the Declaration of Helsinki and International Conference on Harmonization 
Guidelines on Good Clinical Practice and approved by the Ethics Committee of the Canton 
of Basel, Switzerland. The use of MDMA in healthy subjects was authorized by the Swiss 
Federal Office of Public Health, Bern, Switzerland. The studies were registered at 
ClinicalTrials.gov (NCT00886886, NCT00990067, NCT01136278, NCT01270672, and 
NCT01386177). 
 
Participants 
 Eighty healthy subjects (40 men and 40 women) aged 18 to 44 years (mean  SD, 25 
± 5 years) were recruited on the university campus. The exclusion criteria included the 
following: (i) age < 18 or > 45 years, (ii) pregnancy determined by a urine test before each 
test session, (iii) body mass index < 18.5 kg/m2 or > 25 kg/m2, (iv) personal or family (first-
degree relative) history of psychiatric disorder (determined by the structured clinical interview 
for Axis I and Axis II disorders according to the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition [Wittchen et al. 1997], supplemented by the SCL-90-R Symptom 
Checklist [Derogatis et al. 1976; Schmitz et al. 2000]), (v) the regular use of medications, (vi) 
chronic or acute physical illness assessed by physical examination, electrocardiogram, 
standard hematology, and chemical blood analyses, (vii) smoking more than 10 cigarettes 
per day, (viii) a lifetime history of using illicit drugs more than five times, with the exception of 
cannabis, (ix) illicit drug use within the last 2 months, and (x) illicit drug use during the study 
determined by urine tests conducted before the test sessions using TRIAGE 8 (Biosite, San 
Diego, CA). The subjects were asked to abstain from excessive alcohol consumption 
between test sessions and limit alcohol use to one drink on the day before each test session. 
Eight of the 80 subjects had previously tried ecstasy (one to two times). Female subjects 
were investigated during the follicular phase (day 2-14) of their menstrual cycle to account 
for the potential confounding effects of sex hormones and cyclic changes in the reactivity to 
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amphetamines (White et al. 2002). All of the subjects provided their written informed consent 
before participating in the study, and they were paid for their participation. 
 
Measures 
 Pupillometry. Pupillometry was performed 1 h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 
3, 4, 5, and 6 h after MDMA or placebo administration. Pupil function was measured under 
standardized dark-light conditions of 5.7 ± 0.8 lux assessed by a Voltcraft MS-1300 luxmeter 
(Voltcraft, Hirschau, Germany) following a dark adaption time of 1 min. Pupillometry was 
performed using a hand-held PRL-200 infrared pupillometer (NeurOptics, Irvine, CA; Taylor 
et al. 2003). The subjects were instructed to focus on a black dot on a white wall at a 
distance of 4 m. After a 10 s focusing period, measurements were taken for 5 s. During this 
time frame, the following parameters were assessed: dark-adapted pupil diameter (MAX), 
minimal pupil diameter after a light stimulus (MIN), and latency to the pupillary light reflex 
(Fig. 2). The constriction amplitude was calculated as MAX-MIN. The time taken by the pupil 
to recover 75% of the initial resting pupil size after it reached constriction was also assessed. 
The dynamic pupil measurements were triggered by a light impulse of 180 μW intensity and 
167 ms duration. Measurements were performed on both eyes, and the average values were 
used for further analyses. 
 Subjective drug effect. Subjective drug effects were assessed using visual analog 
scales (VASs) reported in detail elsewhere (Hysek et al. 2011, 2012a). In the present report, 
we included only the VAS rating of “any subjective drug effects,” measured using a 100-mm 
horizontal line marked “not at all” on the left and “extremely” on the right. The VAS was 
repeatedly administered 1 h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after 
MDMA or placebo administration. The scale is very sensitive to the overall psychotropic 
effects of MDMA. The comprehensive assessment of different aspects of the psychotropic 
response to MDMA have been presented in the reports of the individual studies (Hysek et al. 
2011, 2012a, 2012b, 2012d; Simmler et al. 2011).  
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Blood pressure, heart rate, and body temperature. Blood pressure and heart rate were 
assessed repeatedly 1h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA 
or placebo administration using an OMRON M7 monitor (Omron Healthcare Europe, 
Hoofddorp, The Netherlands) in the dominant arm and after a resting time of 5 min. 
Measures were taken twice per time point with an interval of 1 min, and the average was 
used for analysis. Mean arterial pressure (MAP) was calculated from diastolic and systolic 
blood pressure using the formula MAP = diastolic blood pressure + (systolic blood pressure 
– diastolic blood pressure)/3. Core (tympanic) temperature was assessed repeatedly in the 
same intervals as blood pressure and heart rate using a GENIUS 2 ear thermometer (Tyco 
Healthcare Group, Watertown, NY, USA).  
 Pharmacokinetics of MDMA. Blood samples were collected before and 0, 0.33, 0.66, 
1, 1.5, 2, 2.5, 3, 4, and 6 h after MDMA or placebo administration, and plasma MDMA levels 
were determined as previously described (Hysek et al. 2012a). The data for the plasma 
concentrations of MDMA were analyzed using noncompartmental methods. Maximal plasma 
concentration and the time to maximal plasma concentration were obtained directly from the 
concentration-time curves of the observed values. Plasma concentrations were only 
determined up to 6 h after MDMA administration because the aim of the study was to assess 
plasma exposure only during the time of the pharmacodynamic effects of MDMA.  
 
Drugs 
 (±) MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was prepared as 
gelatin capsules (100 and 25 mg). Identical placebo (mannitol) capsules were prepared. 
MDMA was administered in a single absolute oral dose of 125 mg. This dose of MDMA 
corresponds to a typical recreational dose or the dose of MDMA used as an adjunct to 
psychotherapy (Mithoefer et al. 2010). In the reboxetine-MDMA study, reboxetine (Edronax; 
8 mg; Pfizer, Zurich, Switzerland) or identical placebo was administered at 8:00 PM on the 
day before the test session and again at 7:00 AM on the test day. MDMA or placebo was 
administered at 8:00 AM, 1 and 12 h after reboxetine. In the duloxetine-MDMA study, 
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duloxetine (Cymbalta; 120 mg; Eli Lilly, Vernier, Switzerland) or identical placebo was 
administered at 8:00 PM on the day before the test session and again at 8:00 AM on the test 
day. MDMA or placebo was administered at 12:00 PM, 4 and 16 h after duloxetine. 
Reboxetine and duloxetine were administered twice at high doses to obtain peak plasma 
concentrations of (mean  SD) 372  34 ng/ml and 107  10 ng/ml, respectively, similar to 
the concentrations reached with chronic daily administration of 4 mg and 60 mg of the drugs, 
respectively (Hysek et al. 2011; Simmler et al. 2011), and as previously used to manipulate 
noradrenergic function in healthy subjects (Roelands et al. 2008). Compliance with the first 
administration of reboxetine and duloxetine on the evening prior to the test day was 
confirmed analytically in plasma (Hysek et al. 2011, 2012d). In the clonidine-MDMA study, 
clonidine (Catapresan; 150 μg; Boeringer Ingelheim, Basel, Switzerland) or identical placebo 
was administered at 8:00 AM, 1 h before MDMA or placebo (9:00 AM; Hysek et al. 2012a). 
Clonidine has previously been shown to produce sympatholytic effects at this dose in healthy 
subjects (Anavekar et al. 1982; Bitsios et al. 1996; Nieuwenhuis et al. 2007) and was 
expected to produce peak plasma concentrations in the range of 0.6-0.7 ng/ml (Anavekar et 
al. 1982; Keranen et al. 1978). In the carvedilol-MDMA study, carvedilol (Dilatrend; 50 mg; 
Roche, Basel, Switzerland) or identical placebo was administered at 8:00 AM, 1 h before  
MDMA or placebo (9:00 AM; Hysek et al. 2012c). The same dose of carvedilol has 
previously been shown to attenuate the smoked cocaine-induced increases in heart rate and 
blood pressure in humans (Sofuoglu et al. 2000) and was expected to produce peak plasma 
concentrations in the range of 120-180 mg/ml (Henderson et al. 2006; Morgan 1994). At this 
dose, carvedilol is expected to inhibit both 1- and -adrenergic receptors (Sofuoglu et al. 
2000; Tham et al. 1995), with 5- to 10-fold higher activity at -receptors (Tomlinson et al. 
1988, 1992). In the doxazosin-MDMA study, continued-release doxazosin (Cardura; 4 mg; 
Pfizer, Zurich, Switzerland) or identical placebo was used. A first dose of 4 mg of doxazosin 
was administered 3 days before MDMA or placebo (-64 h) at 5:00 PM, a second dose of 8 
mg was administered 2 days before MDMA or placebo (-40 h) at 5:00 PM, and a third dose 
of 8 mg was administered the day before MDMA or placebo administration (-16 h) at 5:00 
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PM. The subjects were reminded by a phone call or phone text message to ingest the 
capsules, and medication containers were checked to confirm that the first two doses of 
doxazosin were administered. The last administration was supervised by study personnel at 
the research facility. This administration schedule accounted for the long tmax of 8-10 h of the 
continuous-release formulation of doxazosin and reduced the risk of hypotension (Chung et 
al. 1999). Based on similar dosing regimes in healthy subjects (Chung et al. 1999; Shirai et 
al. 2010), the mean estimated peak plasma concentration of doxazosin was 30  5 ng/ml, 
similar to the concentration with steady state-dosing of 4 mg (Chung et al. 1999). The 
pretreatment times for the administration of the five pretreatments resulted in maximal 
plasma concentrations of the pretreatments at the time of or shortly before the maximal 
effect of MDMA, based on our analytical results ( Hysek et al. 2011; Hysek et al. 2012a, c, d) 
or published data (Anavekar et al. 1982; Chung et al. 1999; Henderson et al. 2006; Keranen 
et al. 1978; Morgan 1994; Shirai et al. 2010). Oral drug administration on the test days was 
supervised by study personnel. 
 
Statistical analyses 
 Maximal effect values (Emax), minimal effect values (Emin; only for clonidine), and 
areas under the effect-time curves were determined with repeated measures. Values from 
the five studies were separately compared using two-way factorial General Linear Models 
repeated-measures analysis of variance (ANOVA), with the factors MDMA (MDMA vs. 
placebo) and pretreatment (pretreatment vs. placebo), using STATISTICA 6.0 software 
(StatSoft, Tulsa, OK). Additionally, MDMA and placebo values from all of the studies were 
pooled and analyzed with MDMA as a single within-subjects factor. Tukey post hoc 
comparisons were performed based on significant main effects or interactions in the ANOVA. 
Analyses of the area under the effect-time curve data yielded identical results to those of the 
maximal values and are therefore not shown. Associations between the pharmacodynamic 
changes and plasma concentration of MDMA were analyzed using Spearman’s rank 
correlations. This first correlation analysis assessed associations of the parameters between 
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subjects (n = 80) for each time point. The mean pharmacodynamic changes after MDMA 
administration for each time point were then plotted against the respective mean plasma 
concentrations of MDMA and graphed as hysteresis curves. Correlations between the 
pharmacodynamic-pharmacokinetic data pairs over time (n = 10 time points) were then 
analyzed using Spearman’s rank correlation. Associations between pupillary function 
parameters and subjective effects were similarly analyzed (n = 11 time points). This second 
correlation analysis assessed the associations of mean parameters over time within the 16 
subjects (n = 9 or 10). The criterion for significance was p < 0.05  
 
Results 
Parameters of pupillary function (placebo condition) 
 Pupillary function parameters were measured 12 times throughout the day in 80 
subjects. For placebomean  SEM values were the following: pupil size = 6.23  0.09 mm, 
pupil size after light = 4.34  0.08 mm, constriction amplitude = 1.90  0.01 mm, and 
recovery time 2.46  0.06 s. Maximal values are shown in Table 1. The diameter of the light-
stimulated pupil correlated with resting pupil size prior to the light stimulus (Rs =0.94, p < 
0.001, n = 80).  
Effects of MDMA on pupillary function  
 MDMA increased pupil size both at rest and after the light stimulus and lowered the 
constriction amplitude compared with placebo (Fig. 3, Table 1). The effect of MDMA on pupil 
size peaked (mean  SEM) 2.3  0.2 h after drug administration at the time of the maximal 
plasma concentration of MDMA and remained high over 6 h in parallel with plasma levels 
that also remained high over 6 h (Fig. 3A). The effect of MDMA on the constriction amplitude 
was maximal 1.7  0.1 h after drug administration and decreased to baseline levels over 6 h 
(Fig. 3B) despite high plasma levels of MDMA. MDMA also prolonged the latency to the 
pupillary light reflex and shortened the recovery time of the pupillary light reflex response 
(Table 1).  
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Subjective effects of MDMA 
 MDMA produced significant subjective drug effects compared with placebo (Table 1). 
In parallel with the constriction amplitude the subjective peak effect was reached 1.5  0.1 h 
after MDMA administration and completely reverted to baseline within 6 h, although the 
plasma levels of MDMA remained high (Fig. 3C). The effects of the pretreatments on the 
subjective response to MDMA are reported in detail elsewhere (Hysek et al. 2011, 2012a, b, 
d; Simmler et al. 2011). Briefly, reboxetine and duloxetine reduced the increases in “any 
subjective drug effect” and other aspects of the subjective effects of MDMA, whereas the 
other pretreatments overall had no effect on the subjective response to MDMA (Hysek et al. 
2012c).  
 
Effects of MDMA on blood pressure, heart rate, and body temperature 
MDMA significantly increased blood pressure, heart rate, and body temperature 
compared with placebo (Table 1, Fig. 3D-F). Similar to the subjective effects, MDMA-induced 
increases in blood pressure and heart rate were short-lasting. 
 
Pharmacokinetics of MDMA 
 Plasma MDMA concentrations are shown in Fig. 3. The peak plasma MDMA 
concentration was (mean  SEM) 243  6 ng/ml. The time to maximum plasma concentration 
was 2.5  0.1 h. 
 
Pharmacokinetic-pharmacodynamic and pharmacodynamic-pharmacodynamic associations 
 The relationships between the concentration of MDMA and its pharmacodynamic 
effects are shown in Fig. 4A-C. The average group pupil size was correlated with the 
average plasma levels of MDMA over time (Rs = 0.77, p < 0.01, n = 9), with moderate 
clockwise hysteresis (Fig. 4A). In contrast, the MDMA-induced reduction in constriction 
amplitude was not significantly associated with the plasma concentrations of MDMA (Rs = 
0.43, p = 0.24, n = 9), attributable to pronounced clockwise hysteresis (Fig. 4B). There was 
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similar marked hysteresis and no association (Rs = 0.48, p = 0.17, n = 9) in the relationship 
between the concentration of MDMA and the group average of the subjective drug effects 
(Fig. 4C). The association between the average subjective effect and pupil size over time 
was relatively strong (Rs = 0.77, p < 0.01, n = 10), but hysteresis was observed in the 
relationship between subjective effects and pupil size over time (Fig. 4D), indicating that the 
subjective effects decreased more rapidly than the mydriasis associated with MDMA. In 
contrast, little or no hysteresis was observed in the plot of the relationship of subjective 
effects with constriction amplitude (Fig. 4E), indicating a closer association and more 
congruent subjective and dynamic pupillary effects of MDMA, also demonstrated by a very 
strong correlation between the means of these two effects over time (Rs = 0.96, p < 0.001, n 
= 10; Fig. 4E). Between-subjects correlations further showed that subjective effects were 
strongly correlated with reductions in the light reflex but not with pupil size (Table 2). There 
were similar strong associations between MDMA-induced reductions in constriction 
amplitude and changes in MAP, heart rate, and body temperature (Rs = 0.98, 0.92, 0.87; all 
p < 0.001, n = 10). MDMA-induced increases in blood pressure and heart rate did not 
correlate with the plasma concentrations of MDMA over time consistent with the reduced 
effect over time despite high plasma concentrations of MDMA (Fig. 3D and 3E). 
The findings from the between-subjects analyses of the correlations between the 
plasma levels of MDMA and pharmacodynamic effects of MDMA for each time point (n = 80) 
are shown in Table 3. The MDMA-induced reductions in the constriction amplitude, pupil size 
after light, the increase in MAP, and the subjective effects were significantly and strongly 
associated with the plasma levels of MDMA (Table 3). Weaker correlations were also found 
between plasma levels of MDMA and pupil diameter, latency, and heart rate (Table 3). 
However, these associations were only observed until peak concentrations were reached. In 
contrast, recovery time and body temperature after MDMA administration were not or only 
weakly and inconsistently associated with plasma MDMA levels (Table 3).  
The MDMA-induced reduction in pupil constriction amplitude was significantly greater 
in subjects with greater MDMA-induced increases in MAP (Rs = 0.56, p < 0.001, n = 80) or 
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more pronounced increases in heart rate (Rs = 0.30, p < 0.01, n = 80) as measured 1 h after 
MDMA administration. In contrast, MDMA-induced changes in the pupil size were not or only 
poorly associated with other autonomic changes across subjects. 
 
Pupillary effects of reboxetine, duloxetine, clonidine, carvedilol, and doxazosin alone andon 
the pupillary response to MDMA 
 The peak effects of the pretreatments are shown in Table 4. The drug effects on pupil 
size over time for all five studies are shown in Fig. 5. Both reboxetine and duloxetine 
increased resting pupil size and pupil size after the light stimulus. Duloxetine also lowered 
the constriction amplitude (Table 4). The effect of the two monoamine uptake inhibitors on 
the static pupil diameter was similar in magnitude to the effect of MDMA (Table 4, Fig. 5A 
and B). In contrast, the effect of MDMA on the constriction amplitude was more pronounced. 
When duloxetine was administered together with MDMA, the drug effects on all static and 
dynamic parameters were non-additive and showed negative synergism, reflected by a 
significant pretreatment  MDMA interaction in the factorial ANOVA. Thus, duloxetine 
prevented the effect of MDMA on pupil function, reflected by the absence of a mydriatic 
effect of MDMA compared with baseline in the duloxetine-MDMA condition and compared 
with the duloxetine-placebo condition (Fig. 5B). Duloxetine also prevented the MDMA-
induced impairment in the pupillary light reflex, although it had a similar effect when 
administered alone compared with placebo. The effects of reboxetine and MDMA on pupil 
size were also non-additive (Table 4, Fig. 5B). However, resting pupil size and pupil size 
after the light stimulus were significantly larger after reboxetine plus MDMA compared with 
MDMA alone. Reboxetine also failed to prevent the effect of MDMA on the pupillary light 
reflex. In the present study, reboxetine also reduced the cardio- and psychostimulant effects 
of MDMA (Hysek et al. 2011), and duloxetine nearly completely prevented the 
cardiovascular, psychotropic, and neuroendocrine effects of MDMA as reported elsewhere 
(Hysek et al. 2012b, 2012d). Clonidine reduced resting pupil size and size after the light 
stimulus (Table 4, Fig. 5C). This effect of clonidine was antagonistic and overall additive with 
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the effect of MDMA (Fig. 5C). Specifically, clonidine did not significantly reduce the effects of 
MDMA on any parameter of pupillary function, although it had significant effects alone and 
reduced the cardiovascular response to MDMA (Hysek et al. 2012a). Clonidine did not 
significantly reduce the mydriatic effects of MDMA, although it produced significant miosis. 
Clonidine also had no effects on the psychotropic response to MDMA as previously reported 
(Hysek et al. 2012a). Carvedilol did not alter the effects of MDMA on pupillary function. In 
contrast, carvedilol decreased the cardiostimulant and thermogenic effects of MDMA in the 
same subjects as reported elsewhere (Hysek et al. 2012c). Carvedilol alone decreased pupil 
size, reflected by a significant main effect of pretreatment in the ANOVA, but the reduction in 
pupil size after carvedilol-placebo treatment compared with the placebo-placebo condition 
(Fig. 5D) was not significant in the post hoc test. Doxazosin alone had no effect on pupil size 
compared with placebo, but nonsignificantly reduced the MDMA-induced increase in pupil 
size (Fig. 5E). 
 
Discussion 
 In the present study, we showed that MDMA impaired the pupillary reflex response to 
light, including inducing a longer latency, reducing the constriction amplitude, and reducing 
the recovery time. MDMA produced mydriasis as previously documented using non-
automated techniques (Farre et al. 2004, 2007; Kolbrich et al. 2008; Mas et al. 1999). MDMA 
also increased blood pressure, heart rate, and body temperature and produced positive 
mood effects as described in detail elsewhere (Hysek et al. 2012b, 2012d).  
 The analyses of the effects of MDMA over time showed a very strong correlation 
between the MDMA-induced reduction in constriction amplitude and the subjective and other 
autonomic effects of the drug. The MDMA-induced reduction in the pupillary light reflex 
normalized over 6 h, similar to the subjective and cardiostimulant drug effects that also 
largely disappeared over 6 h, although the plasma levels of MDMA remained high. Thus, the 
reduced reactivity of the pupil to light is relatively short-lasting and subject to acute 
pharmacological tolerance, similar to the subjective and cardiostimulant effects of MDMA. 
   Hysek and Liechti  
 15 
Clinical examination of pupil function in cases of drug intoxication typically includes both an 
estimation of static pupil size and an assessment of the reactivity to a flashlight stimulus. 
With regard to MDMA intoxication, our findings suggest that the impaired reactivity to light 
indicates MDMA exposure within the past 1-4 h and is a marker for the acute subjective and 
autonomic effects of the drug. In contrast, mydriasis lasts at least 6-10 h (Farre et al. 2007; 
Mas et al. 1999), correlates best with the plasma MDMA concentration changes over time, 
and shows only moderate pharmacological tolerance. The mydriatic responses to two 
successive doses of MDMA separated by 24 h were similar, although the peak concentration 
after the second dose of MDMA increased by 29%, indicating some degree of tolerance 
(Farre et al. 2004). Although the mean group changes in pupil size over time reflected the 
concentration-time curve of MDMA, pupil size did not correlate well with the plasma 
concentrations of MDMA across subjects at various time points in our study or with MDMA 
plasma levels 1.25 h after drug administration in a previous study (Kolbrich et al. 2008). This 
is not surprising because the effects of MDMA on pupil size were maximal at single doses of 
75 mg and did not further increase at 125 mg (Mas et al. 1999). Thus, the lack of an 
association is likely attributable to a ceiling effect of the plasma MDMA concentration-effect 
curve. In contrast, dynamic impairments of the pupil light reflex response were significantly 
associated with plasma MDMA levels or the cardiostimulant effects of MDMA across 
subjects. Evaluating the dynamic pupillary response to light may therefore be a better 
estimation of the time and amount of exposure to MDMA than static pupil size.  
 Both sympathetic and parasympathetic innervations contribute to the regulation of 
pupil size and the reflex response (Loewenfeld 1999). At the level of the iris, the latency to 
and amplitude of the reflex response are mainly determined by parasympathetic activity 
(Heller et al. 1990), whereas redilation is controlled by sympathetic inputs (Loewenfeld 1999; 
Morley et al. 1991). Additionally, parasympathetic function is under tonic noradrenergic 
inhibition centrally at the level of the Edinger-Westphal nucleus where the sympathetic 
stimulation of 2-adrenergic receptors may lower parasympathetic output, resulting in 
“pseudoanticholinergic” mydriasis (Phillips et al. 2000a; Siepmann et al. 2007; Szabadi and 
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Bradshaw 1996). Furthermore, the serotonin system is implicated in pupillary function, 
possibly via 5-HT1A-mediated stimulation of the release of norepinephrine and consequent 
activation of 2-adrenergic receptors (Prow et al. 1996). MDMA mainly releases serotonin 
and norepinephrine (Liechti and Vollenweider 2001; Rothman et al. 2001; Verrico et al. 
2007). Because MDMA affected both the parasympathetic and sympathetic aspects of the 
pupillary reflex response all of the aforementioned mechanisms may be involved in the 
effects of MDMA on pupillary function. 
 The norepinephrine transporter inhibitor reboxetine significantly increased pupil 
diameter at rest and after light consistent with previous studies (Szabadi et al. 1998; 
Theofilopoulos et al. 1995). Reboxetine did not reduce the mydriatic response to MDMA, but 
the effects of the two drugs on pupil size were subadditive. The interactive effect of 
reboxetine and MDMA on pupil size indicates that MDMA produces part of its effects on pupil 
size through the transporter-mediated release of norepinephrine, which is inhibited by 
reboxetine (Hysek et al. 2011). This finding is consistent with the attenuation of the cardio- 
and psychostimulant effects of MDMA by reboxetine (Hysek et al. 2011) and supports the 
view that norepinephrine is involved in the stimulant effects of MDMA. 
 The 1-adrenergic receptor inhibitor doxazosin did not affect pupillary function when 
administered alone but nonsignificantly reduced the mydriatic response to MDMA. Prazosin 
did not antagonize mydriasis induced by norepinephrine or phenylephrine in anesthetized 
cats (Hey et al. 1988; Koss et al. 1988). The data indicate that 1-adrenergic receptors in the 
iris may only minimally contribute to mydriasis induced by systemically administered 
sympathomimetic drugs and that central parasympathetic inhibition may be more relevant. 
The 1--adrenergic receptor inhibitor carvedilol had no significant effect on pupil size 
compared to placebo, consistent with earlier work (Hirohashi et al. 1990) and the absence of 
effects of the -adrenergic receptor blocker propranolol on pupillary function (Koudas et al. 
2009). Carvedilol did not affect the mydriatic response to MDMA, but it reduced other 
autonomic effects of MDMA, including increases in blood pressure and body temperature 
(Hysek et al. 2012c).  
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 Clonidine decreased pupil diameter and enhanced the pupillary reflex, consistent with 
its known sympatholytic effects (Clifford et al. 1982; Morley et al. 1991; Phillips et al. 2000b, 
c). Clonidine also lowered the plasma concentrations of norepinephrine and blood pressure 
in the subjects of the present study (Hysek et al. 2012a). The effect of clonidine on pupil 
function is thought to involve the stimulation of 2-adrenergic receptors on central 
noradrenergic neurons, leading to decreased sympathetic outflow to the iris. The 
enhancement of the parasympathetic light reflex is consistent with clonidine-induced 
disinhibition of the noradrenergic central control of parasympathetic outflow (Phillips et al. 
2000b). Despite its significant sympathicolytic effects (Hysek et al. 2012a), clonidine failed to 
significantly reduce the effects of MDMA on pupillary function. Moreover, clonidine did not 
reduce the MDMA-induced increase in norepinephrine or blood pressure to the same extent 
as it reduced these parameters when administered alone (Hysek et al. 2012a). Thus, the 
sympatholytic effects of clonidine and sympathomimetic effects of MDMA were antagonistic 
in an additive manner, without evidence of interactive effects of the two drugs. The findings 
indicate that 2-adrenergic receptors and the vesicular release of norepinephrine are not 
critically involved in the pharmacological effects of MDMA.  
 The serotonin and norepinephrine transporter inhibitor duloxetine increased resting 
pupil diameter, prolonged the latency to the light reflex, and reduced the reaction to light. 
Identical effects on pupillary function have been reported for the serotonin and 
norepinephrine transporter inhibitor venlafaxine (Bitsios et al. 1999; Siepmann et al. 2007). 
The effects of duloxetine on pupillary function likely involve both enhanced noradrenergic 
neurotransmission in the iris and central sympathomimetic inhibition of the parasympathetic 
outflow to the iris. Additionally, the involvement of the serotonin system is likely. Serotonin 
releasers, including fenfluramine (Kramer et al. 1973), meta-chlorophenylpiperazine 
(Benjamin et al. 1997), and MDMA, and serotonin transporter inhibitors (Nielsen et al. 2010; 
Noehr-Jensen et al. 2009; Schmitt et al. 2002) cause mydriasis. Citalopram and paroxetine 
have also been shown to reduce the constriction amplitude (Nielsen et al. 2010; Noehr-
Jensen et al. 2009), similar to previous observations with duloxetine. Duloxetine may 
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therefore exert its effects on pupillary function via both noradrenergic and serotonergic 
mechanisms. Although both duloxetine and MDMA produced mydriasis, pupil size did not 
further increase after administration of both drugs, suggesting interactive effects of the two 
drugs. Moreover, duloxetine almost completely prevented the effects of MDMA on the light 
reflex. Duloxetine also markedly inhibited the cardiostimulant, psychotropic, and 
neuroendocrine responses to MDMA in the same subjects (Hysek et al. 2012b, 2012d). 
Selective serotonin transporter inhibitors including citalopram, fluoxetine, and paroxetine, 
have previously been shown to attenuate the physiological and psychological effects of 
MDMA in humans (Farre et al. 2007; Liechti et al. 2000; Liechti and Vollenweider 2000; 
Tancer and Johanson 2007). Notably, paroxetine prevented the mydriatic effects of MDMA 
(Farre et al. 2007). Together with the interactive effects of duloxetine and MDMA in the 
present work, the findings provide strong support for a role of serotonin in the mechanism of 
action of MDMA. The reduction of the effects of MDMA on the pupil light reflex by duloxetine 
but not reboxetine supports a central modulatory role of serotonin in the effects of MDMA on 
pupillary function, possibly involving central serotonergic potentiation of noradrenergic 
outflow (Prow et al. 1996). 
 In the present study, we also described the basic characteristics of the pupillary 
reflex. We assessed pupillary function under standardized dark-light conditions, similar to 
other studies of the autonomic effects of pharmaceuticals (Bitsios et al. 1999; Nielsen et al. 
2010; Noehr-Jensen et al. 2009; Phillips et al. 2000c). The values of the latency to the light 
reflex and constriction amplitude obtained in the present study were similar to those 
measured under daylight conditions with the same pupillometer (Taylor et al. 2003), 
indicating that these parameters may not be critically affected by the light conditions. Overall, 
our data indicate that the constriction of the pupil represents a measure that is sensitive to 
pharmacological interventions and may be relatively insensitive to changes in light conditions 
compared with measures of pupil size. 
In summary, MDMA increased pupil size and reduced the response to light. The MDMA-
induced prolongation of the latency to the light reflex and reduction in light-induced miosis 
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indicate indirect central parasympathetic inhibition. The faster recovery reflects increased 
direct sympathomimetic action. Both reboxetine and duloxetine interacted with the effects of 
MDMA on static and dynamic measures of pupillary function supporting a role for both 
norepinephrine and serotonin in the effects of MDMA on pupillary function. MDMA-induced 
mydriasis was associated with the plasma concentration-time curve of MDMA. The reduced 
miotic response to light was highly correlated with the subjective and cardiostimulant effects 
of MDMA, and demonstrated acute pharmacological tolerance. 
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Figure 1. Study diagram. 
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Figure 2. Schematic drawing of the light reflex response. MAX represents dark-adapted 
resting pupil size before the light stimulus. Latency represents the time of the onset of 
constriction. MIN represents minimal pupil size after the light stimulus. The constriction 
amplitude was calculated as MAX-MIN. The 75% recovery time is the time to recover 75% of 
the initial resting pupil size after reaching MIN.  
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Figure 3. Acute effects of MDMA on pupil function. Values are expressed as the mean  
SEM of 80 subjects. MDMA increased resting pupil size compared with placebo (A). The 
mydriatic effect of MDMA remained high in parallel with the plasma concentration of MDMA. 
MDMA reduced the pupil constriction amplitude compared with placebo and this effect 
decreased more rapidly than the plasma concentration of MDMA (B). The subjective (C), 
cardiovascular (D-E), and thermogenic (F) effects of MDMA also disappeared within 6 h 
when the plasma concentrations of MDMA were still high.  
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Figure 4. Pharmacokinetic-pharmacodynamic relationship. MDMA effects plotted against the 
plasma concentrations of MDMA (A-C). The values are expressed as the means of 80 
subjects, with SEM omitted for clarity. The times of pupillometry and blood sampling are 
noted next to each point in minutes or hours after MDMA administration. While pupil size 
remained high (A), constriction amplitude (B) and the subjective effect (C) returned to 
baseline within 6 h when MDMA concentrations remained high. This clockwise hysteresis 
was moderate for the mydriatic effect of MDMA, reflecting well the plasma concentration of 
MDMA (A), but pronounced for the impairment in the pupillary reflex response (B) and 
subjective effect of MDMA (C). The subjective effect of MDMA returned to baseline faster 
than the mydriatic response to MDMA (D). In contrast, the time course of the subjective 
effect of MDMA was more congruent with the time course of the MDMA-induced impairment 
in constriction amplitude (E). 
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Figure 5. Effects of pretreatments, MDMA, and the combination of the pretreatments with 
MDMA and placebo on pupil size over time. MDMA increased pupil size compared with 
placebo in all of the studies (A-E). The pretreatment with reboxetine increased pupil size to a 
similar extent as MDMA alone (A). The effect of MDMA on pupil diameter after reboxetine 
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pretreatment compared with reboxetine was significantly smaller than the effect of MDMA 
compared with placebo (A). Duloxetine increased pupil size similar to reboxetine and MDMA 
(B). Duloxetine pretreatment prevented the further increase in pupil size induced by MDMA 
administration (B). Clonidine significantly reduced pupil diameter (C). The effects of clonidine 
and MDMA on pupil size were additive (C) (Table 2). Carvedilol decreased pupil size (D). 
Similar to the effects of clonidine and MDMA, the effects of carvedilol and MDMA on pupil 
size were additive (D). Doxazosin alone had no effect on pupil size compared with placebo, 
but it tended to nonsignificantly attenuate the mydriatic effect of MDMA (E). The data are 
expressed as mean  SEM values in 16 subjects per study. 
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Table 1. Effects of MDMA 
Placebo 
(mean±SEM)
MDMA 
(mean±SEM)
F1,79= P<
Pupil size (mm) Emax 6.60±0.09 7.58±0.07 288.1 0.001
Pupil size after light (mm) Emax 4.76±0.09 6.86±0.09 646.9 0.001
Constriction amplitude (mm) Emin 1.76±0.06 0.81±0.12 328.0 0.001
Latency (sec) Emax 0.25±0.00 0.33±0.02 16.2 0.001
Recovery time (sec) Emin 1.74±0.06 1.17±0.07 57.3 0.001
Subjective drug effect (%maximum) Emax 3.5±1.7 81.0±2.8 901.2 0.001
Mean arterial pressure (mmHg) Emax 95.0±1.0 114.5±1.2 339.7 0.001
Heart rate (beats/min) Emax 76.0±1.2 96.2±1.9 138.1 0.001
Body temperature ( C) Emax 37.3±0.1 37.6±0.1 26.2 0.001
N=80 (values from all five studies were pooled)
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Table 2. Correlations between MDMA-induced changes in pupillary function and the subjective drug effect
t=0 t=20 min t=40 min t=1h t=1.5h t=2h t=2.5h t=3h t=4h t=6h
Pupil size (mm) NS NS 0.31 0.27 NS NS NS NS NS NS
Pupil size after light (mm) NS NS 0.62 0.51 0.42 0.26 0.27 NS NS NS
Constriction amplitude (mm) NS NS -0.74 -0.61 -0.41 -0.28 -0.28 -0.23 -0.23 NS
Latency (sec) NS NS 0.46 0.29 NS NS NS NS NS NS
Recovery time (sec) NS NS -0.42 -0.31 -0.32 -0.22 -0.38 -0.23 -0.28 -0.32
Values are Spearmann correlation coefficients for significant correlations (P<0.05; P<0.001in bold). NS, not significant. N=80.  
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Table 3. Correlations between the effects of MDMA and plasma concentrations of MDMA 
t=0 t=20 min t=40 min t=1h t=1.5h t=2h t=2.5h t=3h t=4h t=6h
Pupil size (mm) NS 0.46 0.45 0.35 0.27 NS NS NS NS NS
Pupil size after light (mm) NS 0.50 0.64 0.57 0.54 0.53 0.49 0.47 0.34 NS
Constriction amplitude (mm) NS -0.28 -0.40 -0.55 -0.53 -0.60 -0.55 -0.65 -0.48 -0.28
Latency (sec) NS 0.23 0.46 0.33 0.35 NS 0.25 0.25 NS 0.25
Recovery time (sec) NS NS -0.32 NS -0.26 NS -0.37 -0.26 -0.26 NS
Subjective drug effect NS NS 0.68 0.56 0.37 0.31 0.44 0.34 0.46 0.31
Mean arterial pressure (mm Hg) NS 0.22 0.69 0.60 0.47 0.35 0.33 0.29 0.39 NS
Heart rate (beats/min) NS NS 0.61 0.47 0.46 0.32 NS NS NS NS
Body temperature (°C) NS -0.24 NS NS NS NS NS NS NS NS
Values are Spearmann correlation coefficients for significant correlations (P<0.05; P<0.001in bold) between MDMA-induced 
pharmacodynamic changes and plasma levels of MDMA. NS, not significant. N=80
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Table 4. Effects of pretreatments, of MDMA, and of the combination on pupil function
Placebo Pretreatment MDMA
Pretreatment-
MDMA
F1,15 = P< F1,15 = P< F1,15 = P<
Pupil size (mm)
Reboxetine Emax 6.15±0.19 7.22±0.20*** 7.32±0.17*** 8.08±0.18*** 
###
124.8 0.001 160.4 0.001 10.7 0.01
Duloxetine Emax 6.55±0.21 7.30±0.19*** 7.52±0.16*** 7.65±0.16*** 58.9 0.001 37.0 0.001 11.2 0.01
Clonidine Emin 5.86±0.20 4.93±0.22***
###
7.06±0.17*** 6.72±0.15*** 87.9 0.001 59.3 0.001 7.8 0.05
Emax 6.75±0.16 6.35±0.22*** 
###
7.65±0.15*** 7.46±0.16*** 68.7 0.001 12.7 0.01 2.8 NS
Carvedilol Emax 6.88±0.19 6.66±0.16
###
7.63±0.13*** 7.66±0.14*** 99.5 0.001 8.0 0.05 1.2 NS
Doxazosin Emax 6.67±0.20 6.69±0.18
###
7.78±0.12*** 7.53±0.14*** 58.2 0.001 2.7 NS 2.2 NS
Pupil size after light (mm)
Reboxetine Emax 4.23±0.17 5.50±0.22*** 
###
6.65±0.23*** 7.37±0.21*** 
###
289.1 0.001 129.9 0.001 9.3 0.01
Duloxetine Emax 4.78±0.22 5.96±0.26*** 
###
6.94±0.19*** 6.38±0.22*** 
##
108.0 0.001 10.9 0.01 84.2 0.001
Clonidine Emin 3.84±0.64 3.15±0.63** 
###
5.31±0.83*** 5.08±0.97*** 93.1 0.001 24.0 0.001 5.2 0.05
Emax 4.80±0.16 4.47±0.22
###
7.01±0.23*** 6.83±0.24*** 211.2 0.001 8.9 0.01 1.2 NS
Carvedilol Emax 5.10±0.25 4.77±0.17
###
6.82±0.17*** 7.04±0.16*** 202.3 0.001 0.4 NS 2.3 NS
Doxazosin Emax 4.88±0.19 4.88±0.18
###
6.86±0.15*** 6.79±0.16*** 169.4 0.001 0.1 NS 0.2 NS
Constriction amplitude (sec) 
Reboxetine Emin 1.74±0.06 1.62±0.07
###
0.60±0.12*** 0.67±0.10*** 71.8 0.001 0.7 NS 3.0 NS
Duloxetine Emin 1.62±0.05 1.27±0.09** 
###
0.52±0.11*** 1.18±0.06*** 
###
63.9 0.001 12.4 0.01 71.2 0.001
Clonidine Emin 1.81±0.05 1.63±0.08
###
0.58±0.11*** 0.50±0.09*** 72.0 0.001 7.6 0.05 1.0 NS
Carvedilol Emin 1.65±0.10 1.75±0.06
###
0.68±0.11*** 0.49±0.08*** 99.5 0.001 0.7 NS 4.2 NS
Doxazosin Emin 1.76±0.06 1.69±0.05
###
0.81±0.12*** 0.78±0.09*** 79.6 0.001 1.2 NS 0.3 NS
Latency (sec)
Reboxetine Emax 0.244±0.006 0.254±0.007 
##
0.303±0.011*** 0.306±0.015*** 14.8 0.001 2.8 NS 0.0 NS
Duloxetine Emax 0.245±0.005 0.266±0.007 0.423±0.088* 0.275±0.005 4.8 0.05 2.2 NS 3.8 0.07
Clonidine Emax 0.252±0.011 0.251±0.023
##
0.297±0.033** 0.308±0.061*** 30.9 0.001 0.7 NS 0.4 NS
Carvedilol Emax 0.260±0.007 0.262±0.009
##
0.304±0.016** 0.303±0.010
##
15.5 0.001 0.0 NS 0.0 NS
Doxazosin Emax 0.253±0.008 0.249±0.006
#
0.325±0.037* 0.291±0.009 10.4 0.01 1.1 NS 1.1 NS
*<0.05, **<0.01, ***<0.001, compared with Placebo; 
#
<0.05, 
##
<0.01, 
###
<0.001,  compared with MDMA; NS, non significant
mean±SEM values
main effect of 
MDMA
main effect of 
pretreatment
Pretreatment × MDMA
 
 
